Related Experiment Video

Updated: Apr 1, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis

S E Trasino1, X-H Tang1, J Jessurun2

  • 1Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY, USA.

Diabetes, Obesity & Metabolism
|October 15, 2015
PubMed
Abstract

Insights

Retinoic acid receptor (RAR) agonists targeting RARβ2 effectively treat type 2 diabetes and fatty liver disease. These compounds reduce hyperglycemia, insulin resistance, and liver fat accumulation in diabetic mouse models.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) and fatty liver disease (hepatic steatosis) are significant global health challenges.
  • Dysregulation of lipid metabolism and insulin resistance are key pathological features.
  • Retinoic acid receptors (RARs) play a role in metabolic regulation.

Purpose of the Study:

  • To investigate the therapeutic potential of specific retinoic acid receptor (RAR) agonists, particularly for RARβ2, in models of diabetes and fatty liver disease.
  • To evaluate the impact of RARβ2 agonists on metabolic parameters and organ health in obese, diabetic mice.

Main Methods:

  • Administration of synthetic RARβ2 agonists to wild-type mice with high-fat-diet-induced type 2 diabetes.
  • Treatment of ob/ob and db/db mice (genetic models of obesity-associated T2D) with RARβ2 agonists.
  • Assessment of metabolic markers, including hyperglycemia, insulin resistance, body weight, and lipid levels.
  • Analysis of gene expression related to lipogenesis and fatty acid oxidation in key metabolic tissues.
  • Histopathological evaluation of liver, pancreas, and kidney tissues for steatosis and oxidative stress.

Main Results:

  • RARβ2 agonists significantly reduced hyperglycemia, peripheral insulin resistance, and body weight in all tested diabetic mouse models.
  • Treatment led to a dramatic reduction in hepatic steatosis, lipid peroxidation, and oxidative stress in the liver, pancreas, and kidneys.
  • RARβ2 agonists modulated gene expression, decreasing lipogenic factors (e.g., SREBP1) and increasing fatty acid oxidation markers (e.g., CPT1α).
  • Triglyceride levels were lowered in the liver, pancreas, kidneys, and muscle following RARβ2 agonist administration.

Conclusions:

  • Orally active, high-affinity RARβ2 agonists demonstrate rapid efficacy in improving the diabetic phenotype.
  • These agents effectively reduce lipid accumulation in critical insulin target tissues, including the liver.
  • RARβ2 agonists show promise as a novel therapeutic strategy for type 2 diabetes and hepatic steatosis.
Keywords:
antidiabetic drugfatty liverinsulin resistancerenal steatosisretinoidstype 2 diabetes

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.9K
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.6K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
946
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
870
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
945
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K